Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Arcus Biosciences, Inc.

RCUS

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Last trade $16.53
Day change -$0.33 (-1.96%)
Day range $12.59 – $17.11
Volume 1,235,355
Market cap $2.43B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.43B
Price / earnings
—
Price / book
6.78×
Price / sales
24.28×
EV / sales
23.79×
EV / EBITDA
-5.12×

Profitability

Earnings per share
-$3.15
Return on assets
-55.38%
Return on equity
-126.54%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.28×
Current ratio
3.34×
Quick ratio
3.34×
Cash ratio
0.76×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$466M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for RCUS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$9M$41M$17M$33M$26M$160M$28M$26M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$9M$41M$17M$33M$26M$160M$28M$26M
Selling, general and administrative$23M$24M$29M$26M$27M$29M$28M$28M
Research and development$117M$113M$122M$121M$141M$139M$122M$101M
Total operating expenses$140M$137M$151M$147M$168M$168M$150M$129M
Operating income-$131M-$96M-$134M-$114M-$142M-$8M-$122M-$103M
Interest expense-$3M-$3M-$3M-$2M-$3M-$2M-$1M-$2M
Income before taxes-$128M-$91M-$128M-$106M-$135M$0-$112M-$93M
Income taxes$0$0$0$0$0$0$0$1M
Net income-$128M-$91M-$128M-$106M-$135M$0-$112M-$94M
Net income attributable to common shareholders-$128M-$91M-$128M-$106M-$135M$0-$112M-$94M
EBITDA-$129M-$93M-$132M-$111M-$140M-$6M-$119M-$100M
Basic earnings per share-$1.00-$0.72-$1.02-$0.89-$1.27$0.00-$1.14-$1.03
Diluted earnings per share-$1.00-$0.72-$1.02-$0.90-$1.27$0.00-$1.14-$1.03

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?

Summit Therapeutics is expanding its investigational drug ivonescimab beyond non-small cell lung cancer into colorectal and bladder cancer indications. The company has initiated phase III trials for metastatic colorectal cancer and phase II/III studies for advanced bladder cancer. Strategic partnerships with AstraZeneca, GSK, and Arcus Biosciences are evaluating ivonescimab in combination with other cancer therapies, with AstraZeneca committing $2 billion in investment. An FDA decision on ivonescimab for EGFR-mutated NSCLC is expected by November 2026.

Zacks Investment Research

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Biogen is expected to report Q3 2026 earnings on October 28 with a consensus EPS estimate of $2.04 per share (down 57.6% YoY) and revenues of $2.59 billion (up 2% YoY). With a positive Earnings ESP of +1.81% and Zacks Rank #3 (Hold), the company appears positioned to beat consensus estimates. Biogen has beaten EPS estimates in all four of the last quarters.

The Motley Fool

An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run

Juan C. Jaen, president of Arcus Biosciences, sold 68,569 shares for $2.0 million through a trust under a Rule 10b5-1 trading plan, while maintaining ~1.2 million shares. The sale appears motivated by tax and liquidity management following a 200% stock surge. Arcus has refocused on casdatifan, its HIF-2α kidney cancer drug, after discontinuing a lung cancer program, with pivotal Phase 3 readouts expected by year-end.

Benzinga

Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

The article discusses the global surge in cancer cases, particularly among people under 50, and the efforts of biotech companies to develop new therapies to combat this trend. It highlights recent progress and upcoming studies from several companies in the oncology space.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.